Compare Novo Nordisk A/S (NVO) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tempus AI — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Tempus AI trades at $49 (market cap $8.69B). The key difference: Novo Nordisk A/S is far larger — about 25.4× Tempus AI's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| NVO | TEM | |
|---|---|---|
Market Cap | $220.53B | $8.69B |
Sector | Health | Broad Market / Factor |
52-Week High | $71.70 | $103.25 |
52-Week Low | $35.29 | $42.37 |
Enterprise Value | $239.49B | $9.37B |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
